The Multiple Sclerosis Treatment Optimization Program
Abstract Objective To design and implement a health system level intervention to reduce escalating multiple sclerosis (MS) disease modifying treatment (DMT) expenditures and improve outcomes. Methods We conducted stakeholder meetings, reviewed pharmacy utilization data, and abstracted information in...
Saved in:
Main Authors: | Annette Langer‐Gould, Stephen C. Cheng, Bonnie H. Li, Michael H. Kanter |
---|---|
Format: | article |
Language: | EN |
Published: |
Wiley
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/b2d72556b04543fdaace7e951537f3da |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Review of teriflunomide and its potential in the treatment of multiple sclerosis
by: Clemens Warnke, et al.
Published: (2009) -
Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
by: Warnke C, et al.
Published: (2011) -
The role of glatiramer acetate in the early treatment of multiple sclerosis
by: David W Brandes
Published: (2010) -
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
by: Lugaresi A, et al.
Published: (2013) -
Measuring treatment response to advance precision medicine for multiple sclerosis
by: Peter A. Calabresi, et al.
Published: (2021)